Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that raises the body's own growth hormone and IGF-1. Its only regulatory approval — as Egrifta — is for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has resurfaced across peptide-clinic and biohacker channels as a 'clinically proven' visceral-fat and longevity peptide, helped along by 2026 changes that widened compounding access to a batch of peptides.
What separates tesamorelin from most trending peptides is that the loudest claim about it is actually backed by randomized human trials. A 2026 systematic review and meta-analysis in Obesity Research & Clinical Practice pooled five randomized controlled trials of tesamorelin versus placebo in adults with HIV-associated lipodystrophy. It reported a significant reduction in visceral adipose tissue (mean difference roughly -27.71 cm²), a drop in hepatic fat (about -4.28 percentage points), an increase in lean body mass (around +1.42 kg) and higher IGF-1, without serious adverse events or worsening of glucose control.
In its approved setting, tesamorelin cuts visceral fat on the order of 15–18% by CT imaging. That is a genuine, measurable effect on the specific deep-abdominal fat depot linked to metabolic risk — and notably it tends to preserve or add lean mass rather than strip it.
The honest trade-off is the population gap. Every one of those pooled trials was in people with HIV-associated lipodystrophy, a distinct metabolic state; there is no registration-quality RCT showing the same benefit for general-population 'belly fat' or as an anti-aging tool, which is how it is now most often sold. Raising IGF-1 is not consequence-free, reported effects include arthralgia, myalgia, paraesthesia and injection-site reactions, and the visceral-fat reduction reverses once the drug is stopped. Against GLP-1-class drugs, tesamorelin does not drive comparable total body-weight loss — it targets a different fat compartment. The evidence is solid; the extrapolation beyond its studied population is where the marketing outruns it.